MARKET

AIM

AIM

AIM ImmunoTech Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.280
0.000
0.00%
After Hours: 2.230 -0.05 -2.19% 18:45 06/11 EDT
OPEN
2.290
PREV CLOSE
2.280
HIGH
2.310
LOW
2.223
VOLUME
443.98K
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
1.600
MARKET CAP
109.06M
P/E (TTM)
-6.1307
1D
5D
1M
3M
1Y
5Y
AIM ImmunoTech extends prior research agreement to develop Ampligen as new inhalation therapy
AIM ImmunoTech (AIM) announces two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited, with the goal of developing Ampligen as a potential inhalation therapy for
Seekingalpha · 05/27 13:03
AIM Extends Partnership to Advance Ampligen as Covid-19 Therapy
By Matt Grossman AIM ImmunoTech Inc. has extended a research agreement with a subsidiary of Smoore International Holdings Ltd. as part of a project to...
marketwatch.com · 05/27 12:55
BRIEF-AIM Immunotech Announces Two Year Extension Of Agreement With Shenzhen Smoore Technology Limited To Develop And Test A New Inhalation Delivery Device For Ampligen
reuters.com · 05/27 12:46
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore International Holdings Limited (...
GlobeNewswire · 05/27 12:45
AIM Immunotech Extends Partnership With Shenzhen Smoore to Develop Ampligen as Potential COVID-19 Inhalation Therapy
MT Newswires · 05/27 11:13
AIM ImmunoTech completes dosing in Cohort 3 of early-stage Ampligen trial
AIM ImmunoTech (AIM) has completed dosing of Cohort 3 in a Phase 1 study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, as a
Seekingalpha · 05/26 13:30
AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse even...
GlobeNewswire · 05/26 13:29
BRIEF-Aim Immunotech Announces Positive Safety Data From The Third Cohort Of Its Phase 1 Intranasal Clinical Trial
reuters.com · 05/26 13:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIM. Analyze the recent business situations of AIM ImmunoTech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIM stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 93.54K
% Owned: 0.20%
Shares Outstanding: 47.83M
TypeInstitutionsShares
Increased
6
31
New
4
70.90K
Decreased
2
2.90K
Sold Out
7
13.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
No Data
  • All
  • Financials
  • Insiders
More
About AIM
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Webull offers kinds of AIM ImmunoTech Inc stock information, including AMEX:AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.